INTERPACE BIOSCIENCES (IDXG) Company Report

Interpace Biosciences announced preliminary and unaudited 2025 revenue of approximately $38-39 million, with thyroid testing revenue growing 21% over 2024 to $34-35 million.
The company initiated full-year 2026 revenue guidance of approximately $40 million from thyroid testing, projecting 16% growth over 2025.
Interpace has simplified its capital structure by converting all Series C Preferred shares into common stock, resulting in a debt-free balance sheet and positive Net Income and EBITDA operations.
The company plans to seek an uplisting to the Nasdaq Stock Market in 2026.
Following the conversion, pro forma basic shares outstanding total approximately 27.7 million shares.

Jan 20, 2026, 2:05 PM

Interpace Biosciences Repays Debt Early to BroadOak Capital Partners

IDXG

New Projects/Investments

Revenue Acceleration/Inflection

Interpace Biosciences (IDXG) has fully repaid its outstanding term loan facility with BroadOak Capital Partners prior to its maturity date.
This early repayment eliminates related interest expenses and provides increased operational flexibility to support future growth.
According to CFO Chris McCarthy, this action strengthens the company's balance sheet, positioning it to focus resources on driving commercial growth and delivering record testing volumes and revenue for its thyroid tests.

Dec 3, 2025, 5:12 PM

Interpace Biosciences Announces Third Quarter 2025 Financial Results

IDXG

Earnings

Revenue Acceleration/Inflection

New Projects/Investments

Interpace Biosciences reported Q3 2025 revenue of $8.8 million, representing a 22% increase compared to the prior year quarter on a pro forma basis.
The company achieved record thyroid test volumes and thyroid revenue of $8.8 million, up 12% and 22% year-over-year respectively.
Income from continuing operations was $1.0 million for Q3 2025, compared to a loss of $0.7 million in the prior year quarter on a pro forma basis.
Q3 2025 marked the first full quarter of the company operating as a Thyroid-only diagnostics testing company.
Cash collections totaled $10.0 million in Q3 2025, an increase from $7.5 million in the prior year quarter on a pro forma basis, driven by enhanced collection initiatives and strategic investments.